SUBSCRIBE
SUBSCRIBE
News   Drug Development

US Panel Rejects Genentech, Inc.'s Avastin for Treating Breast Cancer

December 5, 2007 | 
1 min read
GAITHERSBURG, Md., Dec 5 (Reuters) - Cancer drug Avastin should not be approved to treat women with breast cancer, a U.S. advisory panel recommended on Wednesday.
Clinical research Postmarket research FDA Approvals
Genentech, Inc.
MORE ON THIS TOPIC
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Black box mockup for cosmetics, perfume, presentation with shadows, isolated on background. Product photo for advertising package. Template for stylish cardboard packaging for goods.
Government
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
February 19, 2026
 · 
3 min read
 · 
Tristan Manalac
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
 · 
3 min read
 · 
Heather McKenzie